At the opening session of ISSAD 2021 (the Global Group B Strep Conference), WHO together with the London School of Hygiene and Tropical Medicine will launch The global value of Group B streptococcus vaccine... Time to act! This new report includes extensive new data and analyses on the impacts of Group B Strep (GBS) bacteria on child survival, disability and preterm births, and present a value case for new maternal vaccines.
The Conference is organized in partnership with the Meningitis Research Foundation (MRF), and is hosted by LSHTM and WHO.
GBS accounts for more than the combined neonatal deaths from tetanus, pertussis, and respiratory syncytial virus, for which maternal vaccines are already in use or advanced stages of development. However, no vaccine is currently available for maternal GBS.
The 2nd International Symposium on ‘Streptococcus agalactiae’ Disease (ISSAD) will cover topics ranging from the GBS disease burden challenges to the epidemiology, immunology, and vaccinology of GBS.
Register here to attend this free virtual global conference: https://www.eventbrite.co.uk/e/issad-conference-2021-registration-155613876293
ISSAD Day 1 from Silverstream TV on Vimeo.